L. Roy Papp & Associates LLP Has $1.02 Million Position in IQVIA Holdings Inc. (NYSE:IQV)

L. Roy Papp & Associates LLP trimmed its position in IQVIA Holdings Inc. (NYSE:IQV) by 2.3% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 4,804 shares of the medical research company’s stock after selling 115 shares during the quarter. L. Roy Papp & Associates LLP’s holdings in IQVIA were worth $1,016,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of IQV. Lazard Asset Management LLC raised its stake in IQVIA by 0.9% in the first quarter. Lazard Asset Management LLC now owns 3,263,944 shares of the medical research company’s stock valued at $825,416,000 after buying an additional 30,014 shares during the period. Canada Pension Plan Investment Board boosted its position in IQVIA by 6.4% during the first quarter. Canada Pension Plan Investment Board now owns 3,191,835 shares of the medical research company’s stock worth $807,183,000 after purchasing an additional 193,304 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in shares of IQVIA by 3.8% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,510,685 shares of the medical research company’s stock valued at $634,927,000 after purchasing an additional 92,293 shares during the last quarter. Capital Research Global Investors raised its position in shares of IQVIA by 7.2% in the first quarter. Capital Research Global Investors now owns 2,138,802 shares of the medical research company’s stock valued at $540,882,000 after purchasing an additional 143,533 shares during the period. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its stake in shares of IQVIA by 339.6% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 2,067,195 shares of the medical research company’s stock worth $478,308,000 after buying an additional 1,597,003 shares during the last quarter. 89.62% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. UBS Group increased their target price on IQVIA from $295.00 to $300.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. JPMorgan Chase & Co. boosted their target price on shares of IQVIA from $260.00 to $288.00 and gave the company an “overweight” rating in a research report on Monday, August 5th. Morgan Stanley raised their price target on shares of IQVIA from $270.00 to $280.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 23rd. Evercore ISI boosted their price objective on shares of IQVIA from $230.00 to $270.00 and gave the company an “outperform” rating in a report on Tuesday, July 23rd. Finally, Truist Financial raised their target price on shares of IQVIA from $292.00 to $300.00 and gave the stock a “buy” rating in a report on Tuesday, July 23rd. Four equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and an average target price of $265.67.

IQVIA Price Performance

IQVIA stock traded up $3.97 during midday trading on Friday, reaching $248.93. The company’s stock had a trading volume of 557,350 shares, compared to its average volume of 1,065,940. The business has a 50-day moving average price of $227.07 and a 200-day moving average price of $232.80. IQVIA Holdings Inc. has a 52 week low of $167.42 and a 52 week high of $261.73. The company has a current ratio of 0.85, a quick ratio of 0.85 and a debt-to-equity ratio of 1.80. The stock has a market cap of $45.38 billion, a PE ratio of 33.93, a price-to-earnings-growth ratio of 2.26 and a beta of 1.49.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Monday, July 22nd. The medical research company reported $2.64 EPS for the quarter, beating analysts’ consensus estimates of $2.57 by $0.07. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The company had revenue of $3.81 billion during the quarter, compared to analysts’ expectations of $3.79 billion. During the same period in the prior year, the company earned $2.22 EPS. IQVIA’s revenue was up 2.3% compared to the same quarter last year. On average, sell-side analysts predict that IQVIA Holdings Inc. will post 10.24 EPS for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.